Pharmacogenomics and epilepsy: the road ahead.
Epilepsy is one of the most common, serious neurological disorders, affecting an estimated 50 million people worldwide. The condition is typically treated using antiepileptic drugs of which there are 16 in widespread use. However, there are many different syndrome and seizure types within epilepsy and information guiding clinicians on the most effective drug and dose for individual patients is lacking. Further, all of the antiepileptic drugs have associated adverse reactions, some of which are severe and life-threatening. Here, we review the pharmacogenomic work to date in the context of these issues and comment on key aspects of study design that are required to speed up the identification of clinically relevant genetic factors.
Molecular & Cellular Therapeutics, the Royal College of Surgeons in Ireland, Dublin, Ireland. gcavalleri@rcsi.ie
Gianpiero L
GL
Cavalleri
Mark
M
McCormack
Saud
S
Alhusaini
Elijah
E
Chaila
Norman
N
Delanty
D000483:Alleles; D000927:Anticonvulsants / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics*; D055106:Genome-Wide Association Study; D006801:Humans; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide
D000927:Anticonvulsants; D054316:Biomarkers, Pharmacological